Mandatory Self‑Declaration and Audit Added to Pharmaceutical Marketing Guidelines

Under the UCPMP 2024, pharmaceutical companies are now obligated to file a self‑declaration stating that they adhere to all ethical marketing standards. This declaration must be accompanied by a detailed disclosure of the marketing budget, including expenditures on CME and CPD initiatives.

The code also provides for independent audits—either random, risk‑based, or scheduled—to verify compliance. Any violation may result in penalties, and the two‑level complaint handling system ensures that grievances are addressed promptly before escalating to the Pharmaceuticals Division for appeal.

These measures are designed to enhance transparency, eliminate conflicts of interest, and promote responsible communication of drug benefits to the medical community.